Dexanabinol; a novel neuroprotective drug in experimental focal cerebral ischemia.

Article Details

Citation
Copy to clipboard

Leker RR, Shohami E, Abramsky O, Ovadia H

Dexanabinol; a novel neuroprotective drug in experimental focal cerebral ischemia.

J Neurol Sci. 1999 Jan 15;162(2):114-9.

PubMed ID
10202976 [ View in PubMed
]
Abstract

The permanent middle cerebral artery occlusion (PMCAO) model was used to investigate the cerebroprotective effects of the synthetic cannabinoid, dexanabinol (HU-211). Dexanabinol is a noncompetitive N-methyl-D-aspartate antagonist, with antioxidant and anti-TNFalpha properties. Twenty hypertensive rats were subjected to PMCAO. Eight were given 4 mg/kg dexanabinol, i.v., 1 h after PMCAO, eight received vehicle and four were not injected Five rats underwent sham surgery. Infarct volumes were assessed, as well as TNFalpha concentrations and NOS activity in brain homogenates. Dexanabinol significantly decreased infarct volumes. It also significantly lowered TNFalpha levels in the ipsilateral hemisphere although not to the level of sham operated rats. No effect could be demonstrated on NOS activity. In conclusion, dexanabinol may be a pluripotent cerebroprotective agent.

DrugBank Data that Cites this Article

Drug Targets
DrugTargetKindOrganismPharmacological ActionActions
DexanabinolTumor necrosis factorProteinHumans
Unknown
Not AvailableDetails